健世科技-B(09877)：LuX-Valve Plus EU TRINITY研究大瓣环患者12个月临床随访结果于EuroPCR 2026发布，展现产品大尺寸优势

智通财经05-21

智通财经APP讯，健世科技-B(09877)发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验(EU TRINITY)研究中大瓣环患者12个月期临床随访结果于EuroPCR 2026(2026欧洲心血管介入会议)发布，展现了其大尺寸优势，预期能够满足广泛的、未被满足的临床需求。LuX-Valve Plus EU TRINITY研究：大瓣环患者12个月期临床随访...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2637715878?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-21 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637715878","market":"sh","top_or_hot":-1,"title":"健世科技-B(09877)：LuX-Valve Plus EU TRINITY研究大瓣环患者12个月临床随访结果于EuroPCR 2026发布，展现产品大尺寸优势","media":"智通财经","content":"<div>\n<p>智通财经APP讯，健世科技-B(09877)发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验(EU TRINITY)研究中大瓣环患者12个月期临床随访结果于EuroPCR 2026(2026欧洲心血管介入会议)发布，展现了其大尺寸优势，预期能够满足广泛的、未被满足的临床需求。LuX-Valve Plus EU TRINITY研究：大瓣环患者12个月期临床随访...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444244.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>健世科技-B(09877)：LuX-Valve Plus EU TRINITY研究大瓣环患者12个月临床随访结果于EuroPCR 2026发布，展现产品大尺寸优势</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n健世科技-B(09877)：LuX-Valve Plus EU TRINITY研究大瓣环患者12个月临床随访结果于EuroPCR 2026发布，展现产品大尺寸优势\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-21 07:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1444244.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，健世科技-B(09877)发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验(EU TRINITY)研究中大瓣环患者12个月期临床随访结果于EuroPCR 2026(2026欧洲心血管介入会议)发布，展现了其大尺寸优势，预期能够满足广泛的、未被满足的临床需求。LuX-Valve Plus EU TRINITY研究：大瓣环患者12个月期临床随访...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444244.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1444244.html","article_id":"2637715878","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637715878","pubTimestamp":1779318617,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，健世科技-B 发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验研究中大瓣环患者12个月期临床随访结果于EuroPCR 2026发布，展现了其大尺寸优势，预期能够满足广泛的、未被满足的临床需求。LuX-Valve Plus EU TRINITY研究：大瓣环患者12个月期临床随访结果-由来自法国波尔多大学医院的Thomas Modine教授发布。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1100":"医疗保健设备","BK4156":"煤与消费用燃料","09877":"健世科技-B"},"translate_title":"Jianshi Technology-B (09877): 12-month clinical follow-up results of LuX-Valve Plus EU TRINITY study patients with large annulus were released in EuroPCR 2026, demonstrating the advantages of large size of the product","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09877":1.5},"content_text":"智通财经APP讯，健世科技-B(09877)发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验(EU TRINITY)研究中大瓣环患者12个月期临床随访结果于EuroPCR 2026(2026欧洲心血管介入会议)发布，展现了其大尺寸优势，预期能够满足广泛的、未被满足的临床需求。LuX-Valve Plus EU TRINITY研究：大瓣环患者12个月期临床随访结果-由来自法国波尔多大学医院的Thomas Modine教授发布。EU TRINITY研究是一项全球前瞻性、多中心、单臂临床试验，主要用于评估LuX Valve Plus于重度三尖瓣反流及外科高危患者中应用的安全性及有效性。该项研究共纳入全球20家中心的161例患者(全分析集+学习曲线)，其中18家中心来自法国、德国、西班牙、丹麦及英国。重度三尖瓣反流患者常伴随有右心和三尖瓣环扩张，是增加三尖瓣反流介入治疗难度的主要原因之一。大瓣环患者鲜有安全、有效的临床治疗方案，存在大量未被满足的临床需求。LuX-Valve Plus共有40mm-70mm七个尺寸的瓣膜。本次EU TRINITY研究中，超过75%的患者使用瓣膜尺寸为55mm、60mm、65mm和 70mm，该部分患者平均年龄77岁，平均Tri-Score高达13.6%;9.7%的患者显示重度(Severe)三尖瓣反流，47.8%的患者显示极重度(Massive)三尖瓣反流，42.5%的患者显示瀑布样(Torrential)三尖瓣反流。12个月期临床随访结果显示出LuX-Valve Plus于大瓣环患者中应用优异的有效性和安全性。(1)于三尖瓣反流等级改善方面，97.8%的大瓣环患者a显示无中度以上反流;(2)于美国纽约心心脏协会心功能改善方面，91.6%的大瓣环患者术后心功能等级提升至I/II级;(3)及于生活品质改善方面，大瓣环患者堪萨斯市心肌病变问卷评分平均提升约17分;此外，大瓣环患者6分钟步行距离平均提升约43米。尽管大瓣环患者基线数据显示术前在三尖瓣反流等级、外科高危程度、右心室功能、右心房容积、三尖瓣瓣环扩张程度等方面均更为严重，并且具有更复杂的解剖结构，但是在EU TRINITY研究中，大瓣环患者12个月期临床随访结果显示了LuX-Valve Plus在大瓣环患者应用持续的、优异的安全性和疗效，三尖瓣反流等级显著改善，右心重构使得心功能持续提高，生活质量明显提升，并且维持较低的复合不良事件发生率。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637715878","isCrawlerRequest":true}